ME 143

Drug Profile

ME 143

Alternative Names: ME-143; NV-143

Latest Information Update: 13 Apr 2016

Price : $50

At a glance

  • Originator Novogen
  • Developer MEI Pharma
  • Class Antineoplastics; Isoflavones; Small molecules
  • Mechanism of Action NADH oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 13 Apr 2016 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 15 Mar 2016 Biomarkers information updated
  • 28 Jun 2012 Marshall Edwards is now called MEI Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top